About

Bruce L. Jacobs is a leading urologic oncologist and health services researcher whose work sits at the intersection of surgical innovation, health policy, and patient-centered outcomes. His research primarily focuses on the diffusion and impact of advanced technologies—particularly robotic surgery and intensity-modulated radiotherapy—in the treatment of prostate and bladder cancers. Jacobs is best known for his landmark study showing that many men at low risk of dying from prostate cancer nonetheless receive advanced, costly treatments (141 citations), a finding that has shaped clinical guidelines and sparked debate on overtreatment. He has also produced influential work on the cost-effectiveness of robotic-assisted procedures, the role of nerve growth factor as a urinary biomarker, and the influence of state certificate-of-need laws on technology adoption. With over 400 citations across his most-cited papers, Jacobs’ research consistently demonstrates how technological diffusion can drive both benefits and unintended consequences in urologic care. His work is essential reading for anyone interested in how surgical robots reshape practice patterns, healthcare costs, and patient outcomes.

Research Focus

Key Achievements

10
H-Index
17
Papers
517
Total Citations
30
Avg Citations/Paper
🏆 Most Cited Paper
Use of Advanced Treatment Technologies Among Men at Low Risk of Dying From Prostate Cancer
141 citations · 2013
📈 Most Prolific Year: 2013 (3 Papers)
🤝 Key Collaborators: 67
🏛 Institutions: University of Pittsburgh, University of Michigan–Ann Arbor, GTx (United States), University of Pittsburgh Medical Center, Medical Protective

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago